Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021
29 Abril 2021 - 8:00AM
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will
report first quarter 2021 financial results on Thursday, May 6,
2021 after the financial markets close, and host its annual
shareholder meeting on May 19, 2021. Details for each is as
follows:
Earnings Conference Call and
Webcast Ziopharm will host a conference call and webcast
for the investment community on May 6, 2021, at 4:30 p.m. EDT. The
conference call can be accessed by dialing 855-327-6837
(U.S. and Canada) or 631-891-4304 (International). The
passcode for the conference call is 10013973. A live webcast may be
accessed using the link here, or by visiting the “Investors”
section of the Ziopharm website at www.ziopharm.com. The call will
be recorded and available for replay on the Company’s website for
approximately 90 days after the call.
Annual Meeting of
StockholdersZiopharm will host its annual meeting
virtually on May 19, 2021 at 9:00 am EDT. Shareholders and
interested stakeholders may attend the meeting by visiting
www.virtualshareholdermeeting.com/ZIOP2021. Shareholders can submit
questions and vote their shares electronically during the meeting
using the same link.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost effective T-cell receptor T-cell therapies based on
its non-viral Sleeping Beauty gene transfer platform, a
precisely controlled IL-12 gene therapy, and rapidly
manufactured Sleeping Beauty-enabled CD19-specific CAR-T
program. The Company has clinical and strategic collaborations with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and Regeneron Pharmaceuticals. For more
information, please visit www.ziopharm.com.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAEVP, Investor Relations and Corporate CommunicationsT:
508.552.9255E: alevy@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about ZIOPHARM Oncology Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias